Cue Biopharma to Host Business Update Call and Webcast : vim

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced

Related Keywords

Boston , Massachusetts , United States , Marie Campinell , Jonathan Pappas , Lifesci Communications , Corporate Communications , Linkedin , International Investors , Nasdaq , Cue Biopharma Inc , Ono Pharmaceutical , Selective Targeting ,